ScienceTechyNews: ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer

10:01 AM
Median time to treatment discontinuation (TTD) on crizotinib was 8.8 months; TTD of patients using entrectinib was 14.6 months. Compared with patients on entrectinib, patients on crizotinib had an additional 44 percent chance that their cancer would resume its growth.

by

Post a Comment

No comments

Subscribe to: Post Comments ( Atom )
Powered by Blogger.